ConductScience.org, home

Paper29946005

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

Flaherty KR and 10 others. Eur Respir J, 2018. Cited by 111 papers, by iCite.

Cite this record

ConductScience Library. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Papers, record 29946005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29946005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
PubMed
Journal
Eur Respir J
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
111
iCite
Relative citation ratio, by iCite
5.14
iCite
Revised in PubMed
2019-06-20
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Flaherty KRKevin R
2Fell CDCharlene D
3Huggins JTJ Terrill
4Nunes HHilario
5Sussman RRobert
6Valenzuela CClaudia
7Petzinger UUte
8Stauffer JLJohn L
9Gilberg FFrank
10Bengus MMonica
11Wijsenbeek MMarlies

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Idiopathic Pulmonary FibrosisMajor topic
IndolesMajor topic
PyridonesMajor topic
Aged
Drug Therapy, Combination
Female
Humans
Internationality
Lung
Male
Middle Aged
Treatment Outcome
Vital Capacity

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02598193Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in30287496
"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis." Kevin R. Flaherty, Charlene D. Fell, J. Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L. Stauffer, Frank Gilberg, Monica Bengus and Marlies Wijsenbeek. Eur Respir J 2018; 52: 1800230.
https://conductscience.org/library/papers/30287496PubMed
Comment in30072545Idiopathic pulmonary fibrosis: time for greater expectations?https://conductscience.org/library/papers/30072545PubMed

Download CSV of comments and corrections

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121729893Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.Chest2011https://conductscience.org/library/papers/21729893PubMed
228257580A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.Am J Respir Cell Mol Biol2017https://conductscience.org/library/papers/28257580PubMed
320935110Clinical course and prediction of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/20935110PubMed
429313949Cancer statistics, 2018.CA Cancer J Clin2018https://conductscience.org/library/papers/29313949PubMed
524836312A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med2014https://conductscience.org/library/papers/24836312PubMed
626647432Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.Eur Respir J2016https://conductscience.org/library/papers/26647432PubMed
725439569Combination therapy: the future of management for idiopathic pulmonary fibrosis?Lancet Respir Med2014https://conductscience.org/library/papers/25439569PubMed
828889759Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.Am J Respir Crit Care Med2018https://conductscience.org/library/papers/28889759PubMed
927903663Beyond a single pathway: combination therapy in pulmonary arterial hypertension.Eur Respir Rev2016https://conductscience.org/library/papers/27903663PubMed
1025504994Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.Eur Respir J2015https://conductscience.org/library/papers/25504994PubMed
1121571362Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet2011https://conductscience.org/library/papers/21571362PubMed
1224836310Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med2014https://conductscience.org/library/papers/24836310PubMed
1321719092Idiopathic pulmonary fibrosis.Lancet2011https://conductscience.org/library/papers/21719092PubMed
1421471066An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/21471066PubMed
1529212837Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.Eur Respir Rev2017https://conductscience.org/library/papers/29212837PubMed
1626846335Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.Respir Res2016https://conductscience.org/library/papers/26846335PubMed
1726915984Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.Respir Med2016https://conductscience.org/library/papers/26915984PubMed
1824639005Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.Adv Ther2014https://conductscience.org/library/papers/24639005PubMed
1926400368Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.Respir Res2015https://conductscience.org/library/papers/26400368PubMed
2026177183An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Am J Respir Crit Care Med2015https://conductscience.org/library/papers/26177183PubMed

See all 23 referencesDownload CSV of references

Cited by66

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.

PMIDTitleJournalYearIn PapersSource
42676572Advances in pharmacotherapy for fibrotic interstitial lung disease.Med Rev (2021)2026https://conductscience.org/library/papers/42676572PubMed
42627051Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).Int J Mol Med2026https://conductscience.org/library/papers/42627051PubMed
42566145IGF2BP3 promotes early angiogenesis in pulmonary fibrosis by stabilizing HIF-1α.Mol Cell Biochem2026https://conductscience.org/library/papers/42566145PubMed
42509443Pirfenidone combined with nintedanib in connective tissue disease - associated interstitial lung disease with radiologic progression during antifibrotic monotherapy: A case series.Clin Rheumatol2026https://conductscience.org/library/papers/42509443PubMed
42325755Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Am J Transl Res2026https://conductscience.org/library/papers/42325755PubMed
42085224Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.Am J Respir Crit Care Med2026https://conductscience.org/library/papers/42085224PubMed
41755466Viral Pathogens and Pulmonary Fibrosis: EMT-Driven Mechanisms and Insights From Traditional Chinese Medicine.Rev Med Virol2026https://conductscience.org/library/papers/41755466PubMed
41471790Recent Updates on Molecular and Physical Therapies for Organ Fibrosis.Molecules2025https://conductscience.org/library/papers/41471790PubMed
41372610Targeting gasdermin D-mediated pyroptosis: a precision anti-inflammatory strategy for acute and chronic lung diseases.Inflammopharmacology2026https://conductscience.org/library/papers/41372610PubMed
40917842New perspectives on the progression of pulmonary fibrosis: the cascade from aberrant microvascular endothelial cell activation to fibrosis.Front Med (Lausanne)2025https://conductscience.org/library/papers/40917842PubMed
40323570Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.Pulm Ther2025https://conductscience.org/library/papers/40323570PubMed
40226606Advances in idiopathic pulmonary fibrosis diagnosis and treatment.Chin Med J Pulm Crit Care Med2025https://conductscience.org/library/papers/40226606PubMed
40137966Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40137966PubMed
40135237Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial.Front Pharmacol2025https://conductscience.org/library/papers/40135237PubMed
40036154Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial.Elife2025https://conductscience.org/library/papers/40036154PubMed
39687964Photosensitive dermatitis caused by nintedanib in a patient of chronic fibrosing interstitial lung disease already on pirfenidone.Indian J Pharmacol2024https://conductscience.org/library/papers/39687964PubMed
39403408Understanding myofibroblast origin in the fibrotic lung.Chin Med J Pulm Crit Care Med2024https://conductscience.org/library/papers/39403408PubMed
39340742Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Pulm Ther2024https://conductscience.org/library/papers/39340742PubMed
38948098Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators.World J Stem Cells2024https://conductscience.org/library/papers/38948098PubMed
38655311Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.Heliyon2024https://conductscience.org/library/papers/38655311PubMed

See all 66 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATHS470PubTator's text mininghttps://conductscience.org/library/genes/470NCBI Gene
GGT12678PubTator's text mininghttps://conductscience.org/library/genes/2678NCBI Gene
GGTLC5P653590PubTator's text mininghttps://conductscience.org/library/genes/653590NCBI Gene
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
PIRFENIDONECHEMBL1256391Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1256391ChEMBL
NINTEDANIBCHEMBL502835Derived from the trial1https://conductscience.org/library/drugs/CHEMBL502835ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29946005

GET https://conductscience.org/api/papers/v1/29946005/references?page=2